A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Lemtrada
(United States) [Available]Synonyms :
Alemtuzumab
Class :
Antineoplastics and Monoclonal Antibody
Brand Name :
Lemtrada
(United States) [Available]Synonyms :
Alemtuzumab
Class :
Antineoplastics and Monoclonal Antibody
Dosage Forms & Strengths
Solution
10mg/ml
30mg/ml
As first course treatment:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 5 days
As second course treatment:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 3 consecutive days given for one year after completion of first course treatment
As maintenance dose:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 3 consecutive days
Dosage Forms & Strengths
Injectable solution
10mg/ml
30mg/ml
For >17 years old:
As first course treatment:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 5 days
As second course treatment:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 3 consecutive days given for one year after completion of first course treatment
As maintenance dose:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 3 consecutive days
may increase the risk or severity of adverse effects when combined
myelosuppressive activities of lipegfilgrastim can increase if alemtuzumab is used in combination
when both drugs are combined, the risk or severity of infection increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of neutropenia increases
when both drugs are combined, there may be an increased effect of immunosuppressive activities of fingolimod
influenza virus vaccine h n live
when both drugs are combined, there may be a reduced effect on the therapeutic activity of the vaccine
influenza virus vaccine live trivalent
when both drugs are combined, there may be a reduced effect on the therapeutic activity of the vaccine
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be a reduced effect on the therapeutic activity of the vaccine
when both drugs are combined, there may be a reduced effect on the therapeutic activity of the vaccine
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be a reduced effect on the therapeutic activity of the vaccine
when both drugs are combined, the risk or severity of adverse effects increases
in combination with ofatumumab, alemtuzumab increases the risk of adverse events.
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of bleeding increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of bleeding increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, the risk or severity of adverse effects increases
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
it may enhance the adverse effects when combined with aducanumab
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
The potential for bleeding risk or its seriousness may elevate when alemtuzumab is used together with troxerutin
When mometasone furoate is used together with alemtuzumab, this leads to enhanced risk or seriousness of adverse outcomes
When alemtuzumab is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
When andrographolide is used together with alemtuzumab, this leads to enhanced risk or seriousness of bleeding
the chances of adverse effects can be raised when alemtuzumab is combined with volociximab
the extent of adverse effects can be raised when alemtuzumab is combination
dengue vaccine efficacy will be reduced by alemtuzumab by immunosuppression
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both the drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk or severity of adverse effects
When both drugs are combined, there may be an increased risk of severe and possibly life-threatening infections
the risk of adverse effects may be increased
Actions and spectrum:
Alemtuzumab is a human IgG-derived monoclonal antibody which binds to the CD52 antigen on T and B lymphocytes, NK cells, and monocytes.
Frequency defined
>10%
Anemia
Nausea
Diarrhea
Oropharyngeal pain
Immunogenicity
Herpes viral infection
Fungal infection
Cytomegalovirus
Nasopharyngitis
Abdominal pain
Vomiting
<10%
Decrease in T-lymphocyte count
Purpura
Influenza
Neutropenic fever
Bronchitis
Febrile neutropenia
Leukopenia
Hiccup
Flatulence
Oral candidiasis
Frequency not defined
Duodenal ulcer
Melena
Peptic ulcer
Pseudomembranous colitis
Colitis
Black Box Warning:
None
Contraindication/Caution:
Contraindications:
Hypersensitivity
HIV
Active infection
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology
It involves lysis of CD52-positive cells through antibody-dependent cytotoxicity, complement activation, and apoptosis.
This action targets to modulate and decrease specific immune cell populations which contributes to therapeutic effects.
Pharmacodynamics:
The presence of CD52 on normal lymphocytes and monocytes predicts increased neutropenia, lymphopenia, and infectious complications.
Administration:
It is administered by intravenous infusion.
Patient information leaflet
Generic Name: alemtuzumab
Pronounced: a-LEM-too-zoo-mab
Why do we use alemtuzumab?
Alemtuzumab is used to treat chronic lymphocytic leukemia (CLL), a type of blood cancer, and multiple sclerosis (MS). It works by targeting and marking abnormal cells for destruction by the immune system and helps regulate immune activity to reduce attacks on the nervous system.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
